Last Update 21 Mar 26

Fair value Decreased 17%

AIDX: Future Margin Gains And New Contracts Will Support Upside Potential

Analysts have trimmed their fair value estimate for Healwell AI to CA$2.85 from CA$3.45. This reflects lower Street price targets, a higher discount rate, more moderate revenue growth assumptions, stronger profit margin expectations, and a reduced future P/E multiple.

Analyst Commentary

Recent Street research on Healwell AI has focused on recalibrating price targets while keeping an eye on how the business can execute against growth expectations and profitability goals. The latest updates point to a more measured stance on near term outcomes, with analysts still weighing the long term potential of the platform against valuation risk.

Bullish Takeaways

Bullish analysts are maintaining positive ratings even as they trim price targets, which suggests ongoing confidence in Healwell AI's core business model and ability to execute.
The revised targets, such as the move to about CA$3.10, still sit above the updated fair value estimate of CA$2.85, indicating some upside potential embedded in current forecasts.
Supportive views appear tied to expectations that stronger profit margin assumptions can support earnings quality, even if revenue growth is modeled more conservatively.
Maintained positive recommendations point to confidence that management can deliver on operational milestones that justify a premium P/E multiple over time, despite the recent reduction in future multiple assumptions.

Bearish Takeaways

Bearish analysts are trimming price targets, including cuts of around CA$0.50 and moves from about CA$3.80 to CA$3.10, which signals more cautious expectations around how quickly Healwell AI can realize growth.
The lower Street targets and higher discount rate highlight concern that execution risk and timing of profitability improvements may not fully support earlier valuation levels.
More moderate revenue growth assumptions show hesitance to underwrite aggressive scaling scenarios, which feeds into reduced future P/E multiples and a tighter valuation framework.
The combination of margin optimism with lower top line expectations creates a mixed setup, where any shortfall in cost control or growth could put additional pressure on the current fair value estimate.

What's in the News

HEALWELL reached 47 peer reviewed publications validating its DARWEN AI platform across multiple disease areas and diverse patient populations, with new research featured at the European Crohn's and Colitis Organisation meeting and in the Journal of Crohn's and Colitis (Key Developments).
New DARWEN AI studies are accepted for major conferences in 2026, covering treatment patterns in inflammatory bowel disease, AI supported Type 2 diabetes care standards in primary care, and analysis of suicidal ideation in plaque psoriasis patients (Key Developments).
The software division signed a multi million dollar Health Information Exchange contract in the U.S., supporting secure data aggregation and exchange for millions of patient records across a state wide network of hospitals, clinics, labs, and public health agencies (Key Developments).
HEALWELL announced its first AI contract in the Middle East with a governmental health system, alongside active deployments of core AI solutions such as SMART Search, SMART Identify, and SMART Summary across healthcare systems in Canada and the U.S. (Key Developments).
WELL Health and HEALWELL launched the first phase of WELLTRUST, a consent driven platform that uses DARWEN AI to match pre consenting patients in WELL operated Canadian clinics with clinical trial opportunities while aiming to meet Canadian privacy and governance standards (Key Developments).

Valuation Changes

Fair Value: Trimmed from CA$3.45 to CA$2.85, a reduction of roughly 17%, reflecting the updated set of inputs.
Discount Rate: Raised slightly from 5.968% to 6.254%, which generally makes future cash flows less valuable in the model.
Revenue Growth: The assumed CA$ revenue growth rate has moved from 41.89% to 26.09%, indicating more moderate expectations for top line expansion.
Net Profit Margin: The projected net margin has been lifted from 5.53% to 8.75%, signaling higher modeled earnings efficiency on each CA$ of revenue.
Future P/E: The assumed future P/E multiple has been reduced from 105.11x to 63.85x, indicating a less aggressive valuation multiple being applied to future earnings.

12 views

Key Takeaways

Refocusing on scalable AI software and strategic acquisitions positions Healwell to capitalize on global healthcare digitization, boosting margins, growth, and recurring revenues.
Integration of advanced AI tools and active partnerships enhances customer retention, cross-selling, and operational efficiencies, supporting sustained value and industry leadership.
Heavy reliance on acquisitions and a risky business model transition create uncertainty around stable, scalable growth and long-term profitability amid significant competitive and integration challenges.

Catalysts

About Healwell AI

A healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.What are the underlying business or industry changes driving this perspective?

The transition to a pure-play AI software and services business, including the planned divestiture of lower-margin clinical and patient service units, is expected to streamline operations and focus resources on scalable, higher-margin offerings; this repositioning should drive sustained improvement in gross margin and EBITDA margin, positively impacting both profitability and valuation.
The rapid expansion of Healwell's global healthcare data platform (via the Orion acquisition and integration with Verosource, IntraHealth, and Pentavere) gives the company unique access to high-quality, interoperable patient data-positioning it to capitalize on the worldwide digitization of health records and growing demand for actionable healthcare AI, which can accelerate organic revenue growth and increase recurring revenue streams.
Strategic integration of advanced AI decision support tools directly into Orion's global healthcare software platform enables "bolt-on" deployments for existing customers and makes cross-selling easier, opening up substantial new addressable markets and driving contract size expansion and customer retention-key levers for future top-line growth.
Secular tailwinds from aging populations, rising chronic disease burdens, and the intensifying mandate for value-based care are accelerating the adoption of predictive analytics and AI in healthcare; Healwell's embedded presence and proven, clinically validated solutions place it at the forefront to benefit from these structural industry shifts, supporting robust, multi-year revenue and earnings growth.
Active pipeline of tuck-in acquisitions and deepening partnerships (notably with WELL Health) add additional catalysts for operating leverage and global scale; this M&A discipline, combined with ongoing cost optimization and shared services initiatives, is likely to result in improving net margins and cash flow generation-supporting long-term shareholder value creation.

Healwell AI Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Healwell AI's revenue will grow by 26.1% annually over the next 3 years.
Analysts are not forecasting that Healwell AI will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Healwell AI's profit margin will increase from -37.2% to the average CA Healthcare industry of 8.7% in 3 years.
If Healwell AI's profit margin were to converge on the industry average, you could expect earnings to reach CA$18.2 million (and earnings per share of CA$0.05) by about March 2029, up from -CA$38.6 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 63.9x on those 2029 earnings, up from -6.2x today. This future PE is greater than the current PE for the CA Healthcare industry at 24.9x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.25%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Revenue growth in recent quarters was primarily driven by large acquisitions such as Orion, with limited information available about underlying organic growth rates and a reliance on lumpy, non-recurring professional services revenue, increasing risk to future top-line growth and revenue stability if acquisitions slow or integration underperforms.
The company is in the midst of a major transition to become a pure-play AI software and services business, divesting its clinical and patient services divisions; this creates operational execution risk, uncertain impacts on gross/net margins, and the potential for near-term revenue and EBITDA volatility as core business lines are redefined.
Healwell's future growth heavily depends on cross-selling and expanding AI solutions across recently acquired platforms and new markets, but successful adoption may be impeded by the long and complex procurement cycles typical in healthcare, potential regulatory challenges, and customer resistance to replacing incumbent systems-posing substantial risks to both revenue scalability and realization of promised operating leverage.
Intensifying competition from global tech giants and established healthcare platform vendors in the AI healthcare space could erode Healwell's pricing power, elevate customer acquisition costs, and reduce overall profitability, leading to sustained margin pressure and lower-than-expected earnings growth.
Successful integration of multiple recent acquisitions (Orion, Verosource, Mutuo, Pentavere, Biopharma) presents significant risks if expected synergies and cost optimizations fail to materialize or if operational complexity impairs focus, thus threatening both margin expansion and the achievement of sustainable, high-quality recurring revenues.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CA$2.85 for Healwell AI based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CA$5.0, and the most bearish reporting a price target of just CA$2.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CA$208.1 million, earnings will come to CA$18.2 million, and it would be trading on a PE ratio of 63.9x, assuming you use a discount rate of 6.3%.
Given the current share price of CA$0.81, the analyst price target of CA$2.85 is 71.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Healwell AI?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Healthcare Digitization Will Transform AI Software Services